Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/5314
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKang, Sebastianen
dc.contributor.authorFletcher, Jamesen
dc.contributor.authorHtut, Sawen
dc.contributor.authorBrown, Amyen
dc.contributor.authorLyle, Meganen
dc.contributor.authorSabesan, Sabeen
dc.contributor.authorJoshi, Abhisheken
dc.date.accessioned2023-06-27T03:03:23Z-
dc.date.available2023-06-27T03:03:23Z-
dc.date.issued2023-
dc.identifier.citationKang, S., Fletcher, J., Htut, S., Brown, A., Lyle, M., Sabesan, S., & Joshi, A. (2023). Administration of immune checkpoint inhibitors at rural towns using the Teleoncology model of care-A North Queensland perspective. The Australian journal of rural health, 31(3), 540–545. https://doi.org/10.1111/ajr.12984en
dc.identifier.urihttps://dora.health.qld.gov.au/qldresearchjspui/handle/1/5314-
dc.descriptionCairns & Hinterland Hospital and Health Service (CHHHS) affiliated authors: James Fletcher, Saw Htut, Megan Lyleen
dc.description.abstractObjective: This study aimed at evaluating the safety of administering immune checkpoint inhibitors (ICIs) and monitoring for immune-related adverse events (irAEs) using the Teleoncology model of care. Design: A retrospective cohort study comparing two patient groups. Setting: The North Queensland Teleoncology Network (NQTN) operated by the Townsville (THHS) and Cairns Hospital Health Services (CHHS) with the Townsville Cancer Centre (TCC) acting as the control group setting. Participants: Patients who received ICI treatment via the NQTN between January 2015 and April 2019. Patients who received ICI at the TCC over the same time period were used for comparison. Main outcome measures: Rates of high-grade irAEs and irAE-related deaths. Results: Fifty-two patients received a total of 822 cycles of ICIs via the Teleoncology model through NQTN. Over the same time period, 142 patients received a total of 1521 cycles at the TCC. There were no significant differences in all demographic characteristics between either group, including tumour profile and Indigenous status. There were no statistically significant differences between the rates of high-grade irAE across multiple body organ systems (p = 0.151) and rate of hospital admissions (13.5% (NQTN) vs 5.6% (TCC), p = 0.702). There were no irAE-related deaths in either group. Conclusions: The results suggest that with adequate governance and clinical resources, ICIs can be administered safely using Teleoncology models to rural and remote towns.en
dc.language.isoenen
dc.relation.ispartofThe Australian journal of rural healthen
dc.subjectimmunotherapyen
dc.subjectirAEen
dc.subjectQReCSen
dc.subjectsafetyen
dc.subjecttelehealthen
dc.titleAdministration of immune checkpoint inhibitors at rural towns using the Teleoncology model of care-A North Queensland perspectiveen
dc.typeArticleen
dc.identifier.doi10.1111/ajr.12984-
dc.identifier.pmid37036295-
item.fulltextWith Fulltext-
item.grantfulltextopen-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.openairetypeArticle-
Appears in Sites:Cairns & Hinterland HHS Publications
Files in This Item:
File Description SizeFormat 
Administration of immune checkpoint inhibitors at rural towns using the.pdf398.13 kBAdobe PDFThumbnail
View/Open
Show simple item record

Page view(s)

72
checked on Dec 24, 2024

Download(s)

92
checked on Dec 24, 2024

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.